Coherus BioSciences (CHRS) Reports In-Line Q1 EPS
Tweet
Share
E-mailGet Alerts CHRS Hot Sheet
Price: $1.49 +0.68%
Revenue Growth %: +91.8%
Financial Fact:
Net sales: 481.26M
Today's EPS Names:
CGEH, NAKA, APOG, More
Revenue Growth %: +91.8%
Financial Fact:
Net sales: 481.26M
Today's EPS Names:
CGEH, NAKA, APOG, More
Join SI Premium – FREE
Coherus BioSciences (NASDAQ: CHRS) reported Q1 EPS of ($0.25), in-line with the analyst estimate of ($0.25). Revenue for the quarter came in at $12.31 million versus the consensus estimate of $14.43 million.
For earnings history and earnings-related data on Coherus BioSciences (CHRS) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Qualcomm plans new chip architecture for phones - Semafor
- Alopexx files for IPO on NYSE American at $10-$12 per share
- Oppenheimer Reiterates Perform Rating on Acadia Pharmaceuticals (ACAD)
Create E-mail Alert Related Categories
EarningsRelated Entities
Earnings, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
